Can Massey Forge Consensus At NSF?

WASHINGTON--Walter Massey, poised to become the next director of the National Science Foundation, has succeeded in a series of tough jobs with an approach built on quiet attention to details and a commitment to reaching a consensus before taking action. It's a style of leadership that differs sharply from the outspoken and authoritarian method of Erich Bloch, whose six-year term ended August 31. And it's one that many scientists who know Massey say will serve him well as the foundation tries to

Written byJeffrey Mervis
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

"He has remarkable people skills," says physicist Gerald Garvey, a senior scientist at Los Alamos National Laboratory and a former associate director for research under Massey at Argonne National Laboratory. "It's quite a contrast to his predecessor at NSF. When you talk with him, you get a sense that the man is genuinely interested in your point of view. And he's very careful to make sure that all sides are being heard."

Adds Roland Schmitt, president of Rensselaer Polytechnic Institute, who served with Massey in the mid-1980s on the National Science Board, which oversees NSF, "He's not quite as blunt as Erich is, but both go after what they want. He'll try to seek a consensus before he acts, but he won't be pushed around."

At the same time, some colleagues wonder if Massey's preference to work for gradual change could prove insufficient to deal with the demands on the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies